Home

The NHLBI Clinical Proteomics Programs were established in July, 2005 to promote systematic, comprehensive, large-scale validation of existing and new candidate protein markers that are appropriate for routine use in the diagnosis and management of heart, lung, blood, and sleep diseases.  The goal of this program is to facilitate validation of protein panels that can be used to predict disease susceptibility, to assist in differential diagnosis, disease staging, selection of individualized therapies, and monitoring of treatment responses.  An additional goal is to establish a high quality education and skills development program to encourage and ensure that scientists develop competencies and expertise needed to address the complex, multifaceted challenges in clinical proteomics.   

The specific goals of the Clinical Proteomics Program are to:

    (1) design panels of candidate proteins for disease areas,

    (2) develop high throughput analytic methods

    (3) assess the predictive value of these proteomic measurements using biological specimens and clinical data from existing study populations

    (4) establish procedures and standards for quality control.